Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade C 37.56 -0.48% -0.18
URGN closed down 0.48 percent on Thursday, May 23, 2019, on 1.55 times normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical URGN trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -0.48%
Fell Below 50 DMA Bearish -0.48%
180 Bearish Setup Bearish Swing Setup -0.48%
Upper Bollinger Band Touch Strength -0.48%

Older signals for URGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Medicine Biopharmaceutical Cancer Surgery Chemotherapy Antineoplastic Drugs Overactive Bladder Non Muscle Invasive Bladder Cancer Interstitial Cystitis
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 61.93
52 Week Low 34.63
Average Volume 106,338
200-Day Moving Average 42.8519
50-Day Moving Average 37.7552
20-Day Moving Average 37.815
10-Day Moving Average 38.406
Average True Range 1.7255
ADX 15.41
+DI 20.0439
-DI 22.6262
Chandelier Exit (Long, 3 ATRs ) 34.7935
Chandelier Exit (Short, 3 ATRs ) 40.6965
Upper Bollinger Band 39.7789
Lower Bollinger Band 35.8511
Percent B (%b) 0.44
BandWidth 10.386884
MACD Line 0.1082
MACD Signal Line 0.1153
MACD Histogram -0.0071
Fundamentals Value
Market Cap 488.62 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -22.49
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.00
Resistance 3 (R3) 40.70 39.25 40.42
Resistance 2 (R2) 39.25 38.38 39.40 40.23
Resistance 1 (R1) 38.41 37.84 38.83 38.71 40.04
Pivot Point 36.96 36.96 37.18 37.11 36.96
Support 1 (S1) 36.12 36.09 36.54 36.42 35.08
Support 2 (S2) 34.67 35.55 34.82 34.89
Support 3 (S3) 33.83 34.67 34.70
Support 4 (S4) 34.13